You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 152 No. 4, April 1998 TABLE OF CONTENTS
  Archives
  •  Online Features
  Special Feature
 This Article
 •Extract
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Lipids and Lipid Disorders
 •Alert me on articles by topic

Picture of the Month

Naji A. Kulaylat, MD; Hassib H. Narchi, MD; Samih A. Baalbaki, MD; Walter W. Tunnessen, Jr, MD
From the Saudi Aramco-Al-Hasa Health Center, Saudi Aramco Medical Services Organization, Mubarraz, Saudi Arabia (Drs Kulaylat, Narchi, and Baalbaki); and The American Board of Pediatrics, Chapel Hill, NC (Dr Tunnessen).

Arch Pediatr Adolesc Med. 1998;152:405-406.

A 13-YEAR-OLD boy, the offspring of first cousins, presented with long-standing, brown-black, hyperpigmented, velvety, hyperkeratotic plaques over both ankles, axillae, neck, and groin (Figure 1). His face was acromegaloid and he had a generalized paucity of subcutaneous fat (Figure 2). His muscles were prominent and his abdomen distended (Figure 3). In addition, he was hirsute and his genitalia were enlarged. A paternal uncle has had similar skin lesions since he was a child.


Figure 1.


Figure 2.


Figure 3.


Denouement and Discussion: Generalized Lipodystrophy

Figure 1. The axilla appears hyperpigmented and velvety, characteristic of acanthosis nigricans.

Figure 2. The face is acromegaloid and the neck shows changes of acanthosis nigricans.

Figure 3. The muscles are prominent and the abdomen is distended secondary to hepatomegaly.

Generalized lipodystrophy, also known as lipoatrophic diabetes, is a progressive multisystem disorder characterized by the loss of subcutaneous and other body fat. The congenital form of generalized lipodystrophy, known as the Lawrence-Seip syndrome, has its onset in the first 2 years of life and is inherited in an autosomal recessive fashion.1 A sporadic, acquired generalized form has its onset in the first to third decades of life. Partial acquired lipodystrophy occurs sporadically and is characterized by the loss of fat in localized areas.

Individuals affected with the generalized form of lipodystrophy develop a cadaveric appearance with acromegalic face and prominent muscles, the result of accelerated growth and the loss of subcutaneous fat. A complete loss of body fat does not occur in generalized lipodystrophy. There seems to be preservation of fat in sites where fat serves a mechanical function.2 Large blood vessels beneath the skin may appear prominent because of the loss of fat. Other features of the disorder are hepatomegaly, acanthosis nigricans, genital hypertrophy, and hirsutism. Metabolic abnormalities include insulin resistance with the eventual development of nonketotic, hyperinsulinemic diabetes mellitus, an increased basal metabolic rate, and hyperlipidemia leading to generalized atherosclerosis with coronary artery disease and fatty infiltration of the liver, eventually leading to cirrhosis and portal hypertension.

Acanthosis nigricans invariably develops in affected individuals as a symmetric dermatosis with a hyperpigmented, velvety appearance that gives a sandpaper-like sensation on palpation. The sites of predilection of acanthosis nigricans include the neck, groin, axillae, and inframammary areas. Affected areas over the knees, elbows, and knuckles have a pebbly feel, more common in the acquired form of the disease. Acanthosis nigricans is associated with other disorders that include obesity, endocrinopathies, autoimmune metabolic diseases, and malignant neoplasms, many of which also feature insulin resistance.3

ENDOCRINE ABNORMALITIES

Hyperinsulinism, a hallmark of lipodystrophy, is due to heterogeneous defects in insulin binding, receptor expression, receptor kinase function, or postreceptor signaling. There is resistance to ketone production secondary to a paucity of stored fat and elevated circulating insulin levels.3 The presence of hypothalamic releasing factors in the serum of some patients with lipodystrophy suggests a lack of hypothalamic regulation.4 The acromegaloid appearance of these patients suggests elevated growth hormone secretion, but their circulating levels of growth hormone and insulin growth factor-1 may be normal, high, or low.5-6 The bone age is usually advanced. Thyroid and adrenal function are generally normal. Plasma glucagon levels range from normal to markedly elevated.7


MANAGEMENT

The treatment of generalized lipodystrophy is supportive. Caloric restriction may improve hyperlipidemia and carbohydrate tolerance. Good control of blood glucose levels is very difficult to achieve because of the underlying insulin resistance. In one report, the selective dopaminergic blocking agent, pimozide, reversed the physical abnormalities as well as the biochemical disturbances.4


AUTHOR INFORMATION

Reprints: Naji A. Kulaylat, MD, Saudi Aramco-Al-Hasa Health Center, Box 6030, Saudi Aramco, Mubarraz 31311, Saudi Arabia.

Accepted for publication August 15, 1997.


REFERENCES

1. Janaki VR, Premalatha S, Rao NR, et al. Lawrence-Seip syndrome. Br J Dermatol. 1980;103:693-696. PUBMED
2. Garg A, Fleckenstein JL, Peshock RM, Grundy SM. Peculiar distribution of adipose tissue in patients with congenital lipodystrophy. J Clin Endocrinol Metab. 1992;75:353-361.
3. Moller DE, Flier JS. Insulin resistance mechanisms, syndromes and implications. N Engl J Med. 1991;325:938-948. ISI | PUBMED
4. Corbin A, Upton GV, Mabry CC, Hollingsworth DR. Diencephalic involvement in generalized lipodystrophy. Acta Endocrinol. 1974;77:209-220.
5. Flier JS, Young JB, Landsberg L. Familial insulin resistance with acanthosis nigricans, acral hypertrophy, and muscle cramps. N Engl J Med. 1980;303:970-973. PUBMED
6. Tzagournis M, George J, Herrold J. Increased growth hormone in partial and total lipodystrophy. Diabetes. 1973;22:388-396. PUBMED
7. Rossini AA, Self J, Aoki TT, et al. Metabolic and endocrine studies in a case of lipoatrophic diabetes. Metabolism. 1977;26:637-650. FULL TEXT | PUBMED

SECTION EDITOR: WALTER W. TUNNESSEN, JR, MD







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1998 American Medical Association. All Rights Reserved.